Monitoring Human Exposome with Extracellular Vesicle Tricorder
Project Number1DP2ES037422-01
Former Number1DP2OD037009-01
Contact PI/Project LeaderLU, YUE
Awardee OrganizationUNIVERSITY OF UTAH
Description
Abstract Text
ABSTRACT
With escalating challenges of climate change and social inequality, there is an urgent need for tools that can
monitor the influences of the exposome on human health across large populations. Due to the heterogeneity and
complexity of biological responses in the body, the capacity to obtain organ-level insights from a simple blood
draw is much desired.
Extracellular vesicles (EVs) are bilayer membrane structures of diameters 30 – 1000 nm, and they are released
into the bloodstream by cells throughout the body, at concentrations on the order of 1010 per ml. Their molecular
content of proteins, dsDNA oligomers, microRNAs, mRNAs, and other analytes, may play multiple functional
roles via EV trafficking, and may also provide a diagnostic report back on the tissue of origin. As such, EVs
provide a unique opportunity to study the health impact of environmental exposures through blood analyses.
The long-term goal of this proposed program is to conduct population-level exposomic surveillance through the
development of a minimally invasive method that can provide a systems view of health status. The method will
be capable of monitoring tissue-specific signatures across individual organs and organ systems through
measurements of circulating EVs. The overall objective of this project is to develop, validate, and apply the
analytical infrastructures (technologies, software, and resources) that powers the method, focusing on
investigating the environmental impact on the human lungs as a proof-of-concept. To establish the technological
foundation of this project, we will integrate an exciting technology trio collectively termed the Extracellular Vesicle
Tricorder. The first technology, VET-seq (Vesicle Epitope Transcript Sequencing), is a droplet-based sequencing
method that resolves the organ source of circulating EVs by detecting EV proteins and RNA cargoes
simultaneously at single-vesicle resolution. The second technology, OrganView, aims to sort and assemble
scrappy information carried by EVs into meaningful biological messages with organ specificity. The third
technology, VPU (Vesicle Processing Unit), integrates a sensitive nanoparticle method, digital microfluidics, and
on-chip immunoassay, to facilitate population-level analysis of EVs.
Towards these challenging goals, I have assembled a multidisciplinary research team to bring together
complementary expertise in micro-nanotechnologies, molecular epidemiology, EV biology, bioinformatics and
statistical modeling, lung cancer, and infectious diseases.
The proposed research is highly innovative because it harnesses an emerging class of analytes (EV omics) to
develop an unconventional systems approach for monitoring the influence of environmental exposures on human
health. Overall, the new concepts, technologies, and resources derived from this work will augment current
methods for exposome research, with the potential to deepen our understanding of human exposome and reveal
unknown health threats in our environment.
Public Health Relevance Statement
PROJECT NARRATIVE
Extracellular vesicles (EVs) are shed into the bloodstream by all cells in the body, providing a unique opportunity
to monitor the health impact of environmental exposures through liquid biopsies. Here we propose a technology
framework integrating bulk and single EV omics, nanotechnologies, and microtechnologies to extract the blood
fingerprints of organ-specific biological responses to life course experiences. The proposed methodologies,
technologies, as well as data sets, will be of high value to both basic and translational research communities.
National Institute of Environmental Health Sciences
CFDA Code
310
DUNS Number
009095365
UEI
LL8GLEVH6MG3
Project Start Date
12-September-2024
Project End Date
31-August-2027
Budget Start Date
12-September-2024
Budget End Date
31-August-2027
Project Funding Information for 2024
Total Funding
$1,386,000
Direct Costs
$900,000
Indirect Costs
$486,000
Year
Funding IC
FY Total Cost by IC
2024
NIH Office of the Director
$1,386,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1DP2ES037422-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1DP2ES037422-01
Patents
No Patents information available for 1DP2ES037422-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1DP2ES037422-01
Clinical Studies
No Clinical Studies information available for 1DP2ES037422-01
News and More
Related News Releases
No news release information available for 1DP2ES037422-01
History
No Historical information available for 1DP2ES037422-01
Similar Projects
No Similar Projects information available for 1DP2ES037422-01